BPC-157 + TB-500 Blend vs TB-500
BPC-157 + TB-500 Blend (Multi-component research blend) and TB-500 (Actin-binding peptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 + TB-500 Blend | TB-500 |
|---|---|---|
| Compound class | Multi-component research blend | Actin-binding peptide fragment |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | Not documented | 7 amino acids |
| Molecular weight | Not documented | ~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form |
| Half-life | Not documented | ~2-3 hours (elimination); tissue effects reported to persist for days |
| Origin | This is a research blend combining BPC-157 and TB-500 (a Thymosin Beta-4-related fragment). It is not a naturally occurring substance and exists only as a combination formulated for research contexts. | TB-500 is a synthetic peptide commonly described as corresponding to the actin-binding domain (a short fragment, often the LKKTETQ region) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is produced synthetically and is not identical to full-length Thymosin Beta-4. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 + TB-500 Blend works
As a blend, it combines the documented properties of its components: BPC-157, studied in animal models for angiogenesis and growth-factor-related tissue-repair signaling, and TB-500, associated with actin regulation and cell migration in preclinical work. Any combined effect is not independently characterized in controlled human trials.
How TB-500 works
Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157 + TB-500 Blend
TB-500
What sets each apart
BPC-157 + TB-500 Blend
This blend pairs a growth-factor/angiogenesis-focused peptide (BPC-157) with an actin-regulating fragment (TB-500), differing from single-peptide or copper-tripeptide products.
TB-500
TB-500 is defined by its actin-binding fragment identity, distinguishing it from BPC-157's growth-factor/angiogenesis focus and from copper tripeptides used cosmetically.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is the BPC-157 + TB-500 blend?
It is a combined research formulation pairing BPC-157 with TB-500 (thymosin beta-4 related peptide), the two most widely co-studied tissue-repair peptides. Vials are commonly supplied at a 1:1 ratio, for example 5 mg of each (10 mg total) or 10 mg of each (20 mg total). Every dose drawn provides both peptides in the same proportion.
Why are BPC-157 and TB-500 combined?
They are combined because their proposed repair mechanisms are viewed as complementary: BPC-157 is associated with angiogenesis and nitric-oxide signaling, while TB-500 relates to actin regulation and cell migration. In tissue-repair research this pairing is the classic 'systemic + local' repair stack. Any synergy claims remain preclinical and unproven in humans.
How is the blend reconstituted and dosed in research?
For a 10 mg blend (5 mg + 5 mg), adding about 3 mL of bacteriostatic water yields roughly 3.33 mg/mL total (about 1.67 mg/mL of each peptide). Because the two peptides differ in typical dosing scale, protocols usually anchor to the TB-500 milligram schedule while accepting the co-delivered BPC-157 amount. These are reference figures, not dosing guidance.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is a research peptide associated with thymosin beta-4 (Tbeta4), a 43-amino-acid actin-binding regulatory peptide. The name TB-500 is used in the research-chemical market for both full-length thymosin beta-4 (MW ~4921 Da) and, in some references, the acetylated active fragment covering residues 17-23 (Ac-LKKTETQ). Buyers should check each vendor's COA, since what is shipped as 'TB-500' varies.
What is TB-500 studied for?
In animal models it is researched for tissue repair, wound healing, angiogenesis, and cell migration, largely through thymosin beta-4's role in sequestering G-actin and regulating the actin cytoskeleton. It has also been examined in cardiac and corneal repair models. Human clinical efficacy has not been established.
What does TB-500's half-life imply for research protocols?
Reported elimination half-life is roughly 2-3 hours, but downstream tissue effects are described as persisting for days through signaling cascades. Because of this, research protocols typically use infrequent dosing (e.g. a few times per week) rather than daily, loading over several weeks before a maintenance phase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.